Membranoproliferative glomerulonephritis Medical Services in China

Membranoproliferative glomerulonephritis (MPGN) is a rare, chronic immune-mediated kidney disease characterized by histopathological changes including mesangial hypercellularity, thickening of the glomerular basement membrane, and duplication of the basement membrane ('double contours') visible on electron microscopy. Historically classified into types I, II (now termed dense deposit disease), and III, MPGN is now redefined based on underlying pathogenic mechanisms—primarily complement dysregulation (e.g., C3 nephropathy, autoantibodies against C3 convertase, or genetic mutations in complement regulators) or immune-complex deposition (often secondary to chronic infections like hepatitis C, autoimmune disorders such as SLE, or monoclonal gammopathies). The disease triggers inflammation and progressive injury to glomeruli, impairing filtration and leading to proteinuria, hematuria, hypertension, and declining glomerular filtration rate (GFR). Epidemiologically, MPGN accounts for <10% of primary glomerulonephritis cases in adults and is even rarer in children; incidence is estimated at 1–2 per million per year globally, with no strong gender predilection but a peak onset in adolescence and early adulthood. Risk factors include inherited complement pathway abnormalities (e.g., factor H, factor I, or MCP mutations), persistent viral infections (especially hepatitis C and less commonly HIV or EBV), autoimmune conditions (SLE, Sjögren’s syndrome), and lymphoproliferative disorders. Untreated or refractory MPGN carries high risk of progression to end-stage kidney disease (ESKD) within 10–15 years in up to 50% of patients. Quality of life is significantly impacted: patients often experience fatigue, edema-related discomfort, anxiety about renal decline, dietary and fluid restrictions, frequent clinic visits and lab monitoring, and psychosocial burden from long-term immunosuppression (e.g., corticosteroids, rituximab, eculizumab). Children may face growth delays and school absenteeism; adults report reduced work capacity, sexual dysfunction, and increased depression prevalence. Early diagnosis via kidney biopsy—including light, immunofluorescence, and electron microscopy—is critical, as treatment response varies substantially by etiology. Complement-targeted therapies have revolutionized management for primary C3-glomerulopathy–associated MPGN, while hepatitis C–related cases require antiviral therapy first. Despite advances, MPGN remains a challenging condition requiring multidisciplinary care involving nephrologists, immunologists, and pathologists to optimize outcomes and preserve kidney function.

Membranoproliferative glomerulonephritis (MPGN) is a rare, immune-mediated pattern of glomerular injury characterized by mesangial hypercellularity, double-contouring of the glomerular basement membrane ('tram-tracking'), and activation of the complement cascade—most commonly via the alternative or lectin pathways. Historically classified into types I, II (dense deposit disease), and III, MPGN is now reclassified based on underlying pathogenic mechanisms: immune-complex–mediated (e.g., secondary to chronic infections, autoimmune diseases, or monoclonal gammopathies) and complement-mediated (e.g., C3 glomerulopathy or autoantibody-driven dysregulation such as C3 nephritic factor). Accurate etiologic diagnosis—via comprehensive serologic testing (C3, C4, CH50, C3NeF, anti-FH antibodies), genetic screening (CFH, CFI, C3, MCP), and renal biopsy with immunofluorescence and electron microscopy—is essential before initiating therapy.

Conservative management forms the cornerstone of early intervention and remains critical across all disease stages. Blood pressure control targets systolic pressure <130 mmHg and diastolic <80 mmHg, achieved primarily with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), which confer dual antiproteinuric and renoprotective effects independent of blood pressure reduction. Dietary sodium restriction (<2 g/day) enhances efficacy of RAAS blockade and mitigates edema. Protein intake is moderated to 0.8–1.0 g/kg/day to reduce glomerular hyperfiltration without inducing malnutrition; in advanced chronic kidney disease (CKD), individualized adjustment per eGFR and nutritional status is mandatory. Lipid management follows KDIGO guidelines: statins are initiated for all patients with persistent proteinuria ≥1 g/day or CKD stage 3+, regardless of baseline LDL, given their pleiotropic anti-inflammatory and endothelial-stabilizing properties. Smoking cessation, vaccination (pneumococcal, influenza, hepatitis B), and avoidance of NSAIDs and nephrotoxic agents are rigorously enforced.

Pharmacotherapy is stratified by etiology and disease activity. For immune-complex–mediated MPGN, first-line treatment includes corticosteroids (e.g., oral prednisone 0.5–1 mg/kg/day tapered over 6 months) combined with cyclophosphamide (oral 1.5–2 mg/kg/day or IV pulse regimens) or mycophenolate mofetil (MMF) (750–1000 mg twice daily) in patients intolerant to alkylating agents. Rituximab (375 mg/m² weekly × 4 or 1000 mg × 2 doses two weeks apart) is increasingly preferred—particularly in post-infectious or autoimmune-associated cases—due to its favorable safety profile and robust B-cell depletion. In complement-mediated MPGN, especially C3 glomerulopathy with documented alternative pathway dysregulation, the monoclonal anti-C5 antibody eculizumab (900 mg IV weekly × 4, then 1200 mg every other week) demonstrates significant stabilization of eGFR and reduction in proteinuria in refractory cases, though cost and infection risk (notably Neisseria meningitidis) necessitate strict vaccination and antibiotic prophylaxis protocols. Emerging agents include ravulizumab (longer half-life C5 inhibitor), iptacopan (oral factor B inhibitor), and danicopan (factor D inhibitor), currently under evaluation in phase III trials. Plasma exchange may be considered acutely in rapidly progressive cases with crescent formation or severe complement activation, particularly when associated with thrombotic microangiopathy.

Surgical intervention has no primary role in MPGN management. However, nephrectomy may be indicated in rare instances of unilateral disease with uncontrollable hypertension or massive hematuria unresponsive to medical therapy—though this is exceedingly uncommon and not evidence-based for typical bilateral MPGN. More relevantly, surgical evaluation focuses on identifying and removing potential antigen sources: excision of chronic infected foci (e.g., dental abscesses, osteomyelitis), resection of lymphoproliferative malignancies (e.g., Waldenström macroglobulinemia), or removal of solid tumors associated with paraneoplastic immune-complex deposition. Liver transplantation is considered in select patients with hereditary complement factor deficiencies (e.g., CFH mutations) complicated by end-stage renal disease, though recurrence risk remains high without adjunctive complement inhibition.

China offers distinct advantages in MPGN care, anchored in integrated multidisciplinary infrastructure and rapid adoption of precision diagnostics. Major tertiary hospitals—including Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—house dedicated glomerular disease registries and perform routine next-generation sequencing for complement genes and mass spectrometry–based proteomic analysis of glomerular deposits, enabling molecular subtyping within 10–14 days. The National Medical Products Administration (NMPA) has expedited approval of eculizumab and rituximab, with subsidized access via the National Reimbursement Drug List since 2022. Furthermore, China leads globally in real-world evidence generation: the China Glomerulonephritis Registry (CGNR) has enrolled >12,000 biopsy-proven cases, informing region-specific treatment algorithms that emphasize early MMF-rituximab combinations for immune-complex disease and tiered complement inhibition strategies. Traditional Chinese Medicine (TCM) adjuncts—such as tripterygium glycosides (used cautiously with monitoring for hepatotoxicity and gonadal suppression) and astragalus-based formulations—are integrated under nephrologist supervision to ameliorate proteinuria and fatigue, supported by randomized controlled trials demonstrating additive antiproteinuric effects when combined with standard immunosuppression.

Recovery and long-term monitoring demand structured, patient-centered follow-up. Patients should undergo quarterly assessments including urinalysis, quantified urine protein-to-creatinine ratio, serum creatinine/eGFR, electrolytes, albumin, C3/C4, and complement functional assays (AP50/CH50). Renal biopsy repeat is recommended at 6–12 months in non-responders to assess histologic response and rule out evolving pathology (e.g., transition to crescentic GN). Lifestyle reinforcement includes supervised low-impact aerobic exercise (150 min/week), dietary counseling by certified renal dietitians, and psychosocial support to address depression/anxiety prevalence exceeding 30% in chronic GN populations. Pregnancy requires preconception counseling: conception is discouraged during active disease or immunosuppression; if pursued, close maternal-fetal surveillance and adjustment to pregnancy-safe agents (e.g., azathioprine instead of MMF, prednisone instead of mycophenolate) are mandatory. Ultimately, MPGN prognosis hinges on timely etiologic diagnosis, early complement or immune modulation, and sustained adherence to conservative measures—making coordinated, longitudinal nephrology care indispensable for preserving renal function and quality of life.